Abstract
Background: Histamine H3 receptor (H3R) is associated with several neuropsychological diseases, and thus it is an important target involved in several CNS disorders, such as narcolepsy, attention deficit hyperactivity disorder and schizophrenia. Since QSAR modeling is a feasible approach to explain the role of the molecular substituents in the biological activity, it can help in improving the design of better H3R ligands for these conditions.
Methods: This article reviews papers previously published in literature to show the current status of the contribution from QSAR modeling to reach H3R antagonists/inverse agonists.
Results: Classical and 3D-QSAR models were retrieved, showing that the steric and hydrophobic properties of the H3R ligands are most important to reach good affinity.
Conclusion: Although QSAR methods are valuable to design better H3R antagonists/inverse agonists, pharmacokinetics should also be considered in future models to ensure good CNS penetration.
Keywords: QSAR, H3 receptor, H3R antagonists, H3R inverse agonists, neurodegenerative diseases, neuropsychiatric disorders, structure-activity relationship.
Graphical Abstract
Current Neuropharmacology
Title:QSAR Modeling of Histamine H3R Antagonists/inverse Agonists as Future Drugs for Neurodegenerative Diseases
Volume: 16 Issue: 6
Author(s): Michelle Fidelis Correa*Joao Paulo dos Santos Fernandes*
Affiliation:
- Departamento de Ciencias Farmaceuticas, Universidade Federal de Sao Paulo, Rua Sao Nicolau 210, Centro 09913- 030, Diadema-SP,Brazil
- Departamento de Ciencias Farmaceuticas, Universidade Federal de Sao Paulo, Rua Sao Nicolau 210, Centro 09913- 030, Diadema-SP,Brazil
Keywords: QSAR, H3 receptor, H3R antagonists, H3R inverse agonists, neurodegenerative diseases, neuropsychiatric disorders, structure-activity relationship.
Abstract: Background: Histamine H3 receptor (H3R) is associated with several neuropsychological diseases, and thus it is an important target involved in several CNS disorders, such as narcolepsy, attention deficit hyperactivity disorder and schizophrenia. Since QSAR modeling is a feasible approach to explain the role of the molecular substituents in the biological activity, it can help in improving the design of better H3R ligands for these conditions.
Methods: This article reviews papers previously published in literature to show the current status of the contribution from QSAR modeling to reach H3R antagonists/inverse agonists.
Results: Classical and 3D-QSAR models were retrieved, showing that the steric and hydrophobic properties of the H3R ligands are most important to reach good affinity.
Conclusion: Although QSAR methods are valuable to design better H3R antagonists/inverse agonists, pharmacokinetics should also be considered in future models to ensure good CNS penetration.
Export Options
About this article
Cite this article as:
Correa Fidelis Michelle *, dos Santos Fernandes Paulo Joao *, QSAR Modeling of Histamine H3R Antagonists/inverse Agonists as Future Drugs for Neurodegenerative Diseases, Current Neuropharmacology 2018; 16 (6) . https://dx.doi.org/10.2174/1570159X15666170818100644
DOI https://dx.doi.org/10.2174/1570159X15666170818100644 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Targeting BLyS in Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Molecular Mechanisms Underlying Specificity of Excitotoxic Signaling in Neurons
Current Molecular Medicine Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Small Molecule Natural Products and Alzheimer’s Disease
Current Topics in Medicinal Chemistry Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry Neuronal Excitability in Epileptogenic Zones Regulated by the Wnt/ Β-Catenin Pathway
CNS & Neurological Disorders - Drug Targets Developing Pharmacotherapies for Cannabis and Cocaine Use Disorders
Current Neuropharmacology AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) The Impact of Ancillary Subunits on Small-Molecule Interactions with Voltage-Gated Potassium Channels
Current Pharmaceutical Design QSAR Studies on some Calcium Channel Blockers
Letters in Drug Design & Discovery Modulators of Voltage-Dependent Calcium Channels for the Treatment of Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Cancer Cell Permeability-Glycoprotein as a Target of MDR Reverters: Possible Role of Novel Dihydropyridine Derivatives
Current Drug Targets AMPA Receptor Positive Allosteric Modulators: Potential for the Treatment of Neuropsychiatric and Neurological Disorders
Current Topics in Medicinal Chemistry Perspectives on the Development of Antioxidant Antiepileptogenic Agents
Mini-Reviews in Medicinal Chemistry Medical Applications of Implantable Drug Delivery Microdevices Based on MEMS (Micro-Electro-Mechanical-Systems)
Current Pharmaceutical Biotechnology